16 Participants Needed

Anabolic Therapy Timing for Osteoporosis

SR
MJ
Overseen ByMackenzie Jordan
Age: 18+
Sex: Female
Trial Phase: Academic
Sponsor: Massachusetts General Hospital
Must be taking: Romosozumab
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

You may need to stop certain medications before joining the trial. Specifically, you should not have taken oral bisphosphonates in the past 3 months, denosumab in the last 12 months, or intravenous bisphosphonates in the past 24 months. Also, you should not have used estrogens, SERMs, calcitonin, or glucocorticoids for more than 14 days in the past 2 months.

What data supports the effectiveness of the drug Romosozumab for osteoporosis?

Research shows that Romosozumab significantly increases bone mineral density (the strength of bones) and bone formation markers in patients with osteoporosis, making it more effective than other treatments like teriparatide. It also controls bone resorption (the process of breaking down bone), which enhances its ability to strengthen bones.12345

Is romosozumab safe for humans?

Romosozumab has been studied for safety in treating osteoporosis, with research indicating it is generally safe but may have potential cardiovascular risks (related to the heart and blood vessels).12467

How is the drug Romosozumab unique in treating osteoporosis?

Romosozumab is unique because it is a monoclonal antibody that both promotes bone formation and inhibits bone resorption by targeting sclerostin, a protein that regulates bone formation. This dual action leads to rapid and significant increases in bone mineral density, making it more effective than other treatments like bisphosphonates or parathyroid hormone analogs, and it is administered once a month through two injections.158910

What is the purpose of this trial?

The aim of this study is to investigate the effect of romosozumab on bone cells during early and late phases of treatment.

Research Team

BL

Benjamin Leder, MD

Principal Investigator

Mass General Brigham

Eligibility Criteria

This trial is for postmenopausal women over 45 with osteoporosis who are not at high risk for bone procedures and have been prescribed romosozumab. They mustn't have other bone diseases, recent use of certain hormones or steroids, major psychiatric conditions, low vitamin D levels, high PTH levels, prior romosozumab exposure, substance abuse issues, or severe kidney disease.

Inclusion Criteria

I am postmenopausal, with no period for over 3 years or had a hysterectomy with high FSH levels if I'm under 60.
I am eligible for romosozumab treatment according to FDA guidelines.
Not at increased risk for a bone marrow aspirate or bone biopsy
See 2 more

Exclusion Criteria

You drink too much alcohol or use drugs in a way that would make it hard for you to understand the study or follow the study rules.
I have previously been treated with romosozumab.
I haven't taken oral bisphosphonates in the last 3 months, denosumab in the last year, or IV bisphosphonates in the last 2 years.
See 6 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Pre-Treatment Biopsy

Participants undergo a bone biopsy procedure prior to starting romosozumab therapy

1 day
1 visit (in-person)

Early Treatment

Participants receive romosozumab therapy and undergo a second bone biopsy 3-6 weeks after starting therapy

3-6 weeks
1 visit (in-person)

Late Treatment

Participants continue romosozumab therapy and undergo a second bone biopsy 6-8 months after starting therapy

6-8 months
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Biopsy
  • Romosozumab
Trial Overview The study examines the effects of a medication called romosozumab on bone cells in women with osteoporosis. It compares results from early versus late treatment phases to understand how this drug works over time.
Participant Groups
2Treatment groups
Active Control
Group I: Late BiopsyActive Control1 Intervention
The investigators will perform paired iliac crest bone biopsies in postmenopausal women who meet standard romosozumab treatment indications and are being prescribed romosozumab by their treating physician. All study volunteers will have a bone biopsy procedure prior to starting therapy, and then an identical procedure at the contralateral side either 3-6 weeks ("early") or 6-8 months ("late") after starting therapy. This is not a clinical trial: the investigators will not be assigning volunteers to a specific osteoporosis therapy, though the investigators will randomize volunteers to either the early or late second biopsy.
Group II: Early BiopsyActive Control1 Intervention
The investigators will perform paired iliac crest bone biopsies in postmenopausal women who meet standard romosozumab treatment indications and are being prescribed romosozumab by their treating physician. All study volunteers will have a bone biopsy procedure prior to starting therapy, and then an identical procedure at the contralateral side either 3-6 weeks ("early") or 6-8 months ("late") after starting therapy. This is not a clinical trial: the investigators will not be assigning volunteers to a specific osteoporosis therapy, though the investigators will randomize volunteers to either the early or late second biopsy.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Massachusetts General Hospital

Lead Sponsor

Trials
3,066
Recruited
13,430,000+

Findings from Research

In a study of 130 postmenopausal osteoporosis patients, those who were treatment-naïve showed the greatest increase in lumbar spine bone mineral density (BMD) after six months of romosozumab treatment, with a 13.6% increase compared to lower increases in patients previously treated with bisphosphonates, denosumab, or teriparatide.
The early changes in bone turnover markers, specifically PINP and TRACP-5b, were significant predictors of the increase in lumbar spine BMD, indicating that monitoring these markers could help assess treatment response to romosozumab.
Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis.Ebina, K., Hirao, M., Tsuboi, H., et al.[2021]
Romosozumab significantly reduces the risk of fractures in postmenopausal women with osteoporosis, showing a 63% lower risk of new vertebral fractures and a 41% lower risk of hip fractures compared to other therapies, based on data from six randomized controlled trials involving over 5,600 participants.
The treatment also leads to substantial increases in bone mineral density (BMD) at key sites like the lumbar spine and hip, while demonstrating a good safety profile with no significant increase in adverse events compared to other treatments.
Romosozumab treatment in postmenopausal women with osteoporosis: a meta-analysis of randomized controlled trials.Liu, Y., Cao, Y., Zhang, S., et al.[2019]
In a study of 148 postmenopausal osteoporosis patients, those who were treatment-naïve showed the greatest increase in bone mineral density (BMD) after 12 months of romosozumab treatment, with an 18.2% increase in lumbar spine BMD compared to lower increases in patients previously treated with bisphosphonates or other therapies.
The effectiveness of romosozumab in increasing BMD was significantly influenced by the type of prior treatment and early changes in bone turnover markers, indicating that these factors can help predict treatment response.
Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis.Ebina, K., Tsuboi, H., Nagayama, Y., et al.[2021]

References

Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis. [2021]
Romosozumab treatment in postmenopausal women with osteoporosis: a meta-analysis of randomized controlled trials. [2019]
Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis. [2021]
Time-Course Changes in Bone Metabolism Markers and Density in Patients with Osteoporosis Treated with Romosozumab: A Multicenter Retrospective Study. [2021]
Romosozumab/CDP7851 for the treatment of osteoporosis. [2019]
Romosozumab: a Review of Efficacy, Safety, and Cardiovascular Risk. [2021]
Romosozumab: A Novel Injectable Sclerostin Inhibitor With Anabolic and Antiresorptive Effects for Osteoporosis. [2021]
Clinical Utility of Romosozumab in the Management of Osteoporosis: Focus on Patient Selection and Perspectives. [2022]
Romosozumab: A Review in Postmenopausal Osteoporosis. [2021]
Romosozumab: a novel bone anabolic treatment option for osteoporosis? [2020]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security